ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Upstream depends on being able to display ads on our services in order to finance our journalism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback